Or, maybe, and hear me out, don't get on the internet and make a fool of yourself? You have zero idea what went into conceiving, developing, testing, or approving this or any medication.
Phase 3 trails are to determine if a drug works in a statistically meaningful population. While safety data is also analyzed, much of that work was done before the phase 3 study. This drug has been in development for years. You can't start a phase 3 trial without already showing that the potential drug is likely safe. BMS bought the company that did all the early heavy lifting with this drug. It was known as KarXT for years if you want to dig up the data.
You literally fucccking though they just decided 5 weeks ago to start dosing people with some random chemical mixture. And the EFFICACY for this drug apparently can be assessed over 5 weeks. Do you know some drugs are SINGLE DOSE? And can be evaluated in a very short time frame? Did you want to rerun trials of those where people take it (needlessly) for months on end?? What sense would that make?
Do yourself a favor and STOP TALKING.
+1
anyone who is involved in clinical trials is shaking their heads at the comments in this thread.
I’ve been pleasantly surprised to see other Letsrun posters work are involved with clinical research jump in. It’s always so aggravating to read things like this from people who have zero clue about drug and medical device development.
While I'm kind of impressed to OP has not deleted this thread, this is example one million of disinformation circling the globe before the truth can get its pants on.
This medicine is actually a combination of two drugs that were discovered decades ago. One in the 60s and the other in the late 90s. The 90s drug failed during clinical trials, but when combined with the 60s drug, the toxicity was neutralized. Both drugs have had extensive testing in humans and I suppose this is why the approval is relatively quick. Interestingly, the actual cost of goods for the mixture is probably a small fraction of the yearly cost, but the actual costs of development are being recouped and profit for investors being captured with the high current cost. Clearly this is a combination that will be much less costly once it is generic.